



August 11, 2025

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051

Scrip Code: 544008

SYMBOL: MAXESTATES

Sub: Newspapers publication regarding the Financial Results for the quarter ended June 30, 2025.

Dear Sir/Madam,

Please find enclosed copies of newspaper advertisements regarding the publishing of Unaudited Financial Results (both standalone and consolidated) for the quarter ended June 30, 2025.

This is for your information and records.

Thanking you,

Yours faithfully,

For Max Estates Limited

Abhishek Mishra
Company Secretary & Compliance Officer

Encl: a/a

Max Estates Limited

Corporate Office: Max Towers, L-20, C-001/A/1, Sector-16B, Noida-201301, Uttar Pradesh, India, | P: +91 120-4743222
Regd. Office: Max House 1, Dr. Jha Marg, Okhla Phase 3, Opposite Okhla Railway Station, Okhla Industrial Estate, New Delhi -110020

Email : secretarial@maxestates.in | Website : www.maxestates.in | CIN: L70200DL2016PLC438718

E-commerce, Tier-2 demands push India’s Korean beauty wave

SUGANDHA MUKHERJEE
New Delhi, August 9

INDIA’S FAST-CHANGING e-commerce and retail landscape is opening new growth avenues for beauty brands, with Korean beauty emerging as one of the biggest beneficiaries. Speaking at the ‘Rise of Korean Beauty in India’ event, hosted by KindLife and Datum Intelligence, Satish Meena, co-founder of Datum, said the brands seeing the strongest performance tend to either focus on a tight set of repeat SKUs with proven quality, which builds loyalty and

repeat purchases, or adopt a mass-market strategy with distribution already in place. He pointed to fast-fashion brand Zudio’s expansion into beauty retail as an example. “They know their distribution is sorted, the customer is coming, they have a proper price for it, and they can sell more and more to their customers,” Meena said. Quick commerce, he added, has become an increasingly important channel for new and emerging beauty brands. It speeds up purchase decisions, with consumers willing to receive products in



10 minutes instead of waiting a day for delivery from Amazon or other e-commerce platforms. “It’s a good tool for brands to self-align to customers,” he said. “Some clients are even using it to segment their service codes and pick up their customers accordingly.” This acceleration in retail channels is coinciding with a

sharp rise in the Korean beauty segment in India. Radhika Ghai, co-founder of KindLife, said interest in Korean beauty is no longer limited to metropolitan areas. “We are seeing huge traction from tier-2 and tier-3 towns as well,” she noted, adding that social media and YouTube have fuelled widespread curiosity about K-beauty products since KindLife’s launch shortly after the Covid pandemic. Research presented at the event showed the K-beauty market is expected to grow from \$400 million in 2024 to \$1.5 billion by 2030, a compound annual growth

rate of 25.9%.The number of buyers is forecast to more than double, from 11.9 million to 27.2 million over the same period. The growth reflects broader shifts in India’s \$45 billion beauty and personal care market. Korean beauty’s popularity has been boosted by the spread of South Korean culture, from music to television. Netflix reported a 370% rise in Korean drama viewership in India in 2020, while K-pop streams reached 6.2 billion in 2023, placing the country among the top five markets globally. Imports of Korean instant

noodles rose 162% in 2020, underscoring the wider appeal of Korean products. More than half of Indian consumers say they actively use or follow K-beauty, and one-third have tried at least one product. Discovery is mainly digital, led by YouTube and Instagram, while influencers and reviews remain key purchase drivers. With expanding retail reach, rapid delivery channels and strong cultural pull, K-beauty’s growth trajectory reflects the new realities of India’s e-commerce-led beauty boom.

● 'SETTLED CONFLICT'

Trump brings back his Indo-Pak claims

PRESS TRUST OF INDIA
Washington, August 9

US PRESIDENT DONALD Trump repeated the claim that he got “things settled” between India and Pakistan following the four-day military conflict between the two countries that could have turned into a “nuclear conflict”. Speaking at the White House on Friday, Trump also claimed that five or six planes “got shot down” during the recent conflict between the South Asian neighbours. The US president did not specify whether the jets were lost by either of the two countries or if he was referring to combined losses by both sides. New Delhi has been maintaining that India and Pakistan halted their military actions following direct talks between their militaries without any mediation by the US. Trump made the comments flanked by Azerbaijan



US President Donald Trump gestures during a trilateral signing ceremony with Armenian Prime Minister and Azerbaijani President at the White House on Friday

President Ilham Aliyev and Armenia’s Prime Minister Nikol Pashinyan after they inked a US-brokered peace agreement during a trilateral signing ceremony. “As President, my highest aspiration is to bring peace and stability to the world. Today’s signing follows our success with India and Pakistan.” Asserting that he is settling conflicts through trade, he

said, “I got things settled with India, Pakistan. I think it was trade more than any other reason. That’s how I got involved.” Trump referred to the conflict between India and Pakistan twice during his remarks at the event, adding them to the nearly 35 previous occasions where he has claimed that he stopped the war between the two countries through trade.

Israel’s takeover plans alarming, says Guterres

ANI
New York, August 9

THE UNITED NATIONS secretary-general Antonio Guterres is “gravely alarmed by the decision of the Israeli Government to ‘take control of Gaza City’”. He said this decision “marks a dangerous escalation and risks deepening the already catastrophic consequences for millions of Palestinians, and could further endanger more lives, including of the remaining hostages.” The secretary-general highlighted that Palestinians in Gaza continue to endure “a humanitarian catastrophe of horrific proportions.” He reiterated his urgent appeal for “a permanent ceasefire, unimpeded humanitarian access across Gaza, and for the immediate and unconditional release of all hostages.” Guterres once again “strongly urges the Government of Israel to abide by its



UN secretary-general Antonio Guterres

obligations under international law.” He recalled that the International Court of Justice, in its Advisory Opinion of 19 July 2024, declared, inter alia, that the State of Israel is under an obligation to “cease immediately all new settlement activities, and to evacuate all settlers from the Occupied Palestinian Territory, and to bring to an end its unlawful presence in the Occupied Palestinian Territory.”

A minute’s silence for Nagasaki



People observe a minute's silence at the Atomic Bomb Hypocenter Park in Nagasaki to mark the 80th anniversary of the city's atomic bombing, on Saturday

REUTERS
Nagasaki, August 9

THOUSANDS BOWED THEIR heads in prayer in Nagasaki on Saturday to mark the 80th anniversary of the city’s atomic bombing, as the mayor warned that current global conflicts could push the world again into nuclear war. The western Japanese city was levelled on August 9, 1945, when the United States dropped

a 10,000-pound plutonium-239 bomb, nicknamed “Fat Man”, instantly killing some 27,000 of the city’s estimated 200,000 people. By the end of 1945, the death toll from acute radiation exposure had reached about 70,000. Nagasaki’s destruction came three days after a U.S. uranium-235 bomb destroyed Hiroshima. Japan surrendered on August 15, ending World War Two.

After a moment of silence at 11:02 a.m., marking the time of the blast, Mayor Shiro Suzuki called on leaders to return to the principles of the U.N. Charter and show a concrete path toward abolishing nuclear weapons, warning that delay was “no longer permissible.” “This is a crisis of human survival that is closing in on each and everyone of us,” Suzuki told the crowd, estimated by Japanese media at 2,700.

MAX ESTATES LIMITED
CIN: L70200DL2016PLC438718
Corporate Office: Max Towers, L-20, C-001/A/1, Sector-16B, Noida-201301, Uttar Pradesh, India
Registered Office: Max House 1, Dr. Jha Marg, Okhla Phase 3, Opposite Okhla Railway Station, Okhla Industrial Estate, South Delhi, New Delhi, India, 110020
Website: www.maxestates.in

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

The Board of Directors of the Company, at the meeting held on August 08, 2025, approved the unaudited financial results of the Company for the quarter ended June 30, 2025.

The results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com, and on the company's website (URL: https://maxestates.in/wp-content/uploads/2025/08/Outcome-of-Board-Meeting-08.08.2025.pdf). The same can be accessed by scanning the Quick Response Code provided below.

By Order of the Board
For **Max Estates Limited**
Sd/-
Sahil Vachani
Vice-Chairman & Managing Director

Note - The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

KOKUYO CAMLIN LIMITED
Regd. Office: Hilton House, 48/2, Central Road, M.I.D.C, Andheri (E), Mumbai - 400 093.
CIN: L24223MH1946PLC005434; Tel: 91-22-6655 7000; Fax: 91-22-2836 6579;
E-mail: investorrelations@kokuyocamlin.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025
(₹ In Lakhs)

Sr. No.	Particulars	Three months ended		Year ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited	Unaudited	Audited
1	Total income from operations	22,739.23	20,003.36	22,941.81	76,252.88
2	Net profit for the period (before tax, exceptional and /or extraordinary items)	1,352.76	679.83	2,168.21	874.82
3	Net profit for the period (before tax after exceptional and /or extraordinary items)	1,352.76	679.83	2,168.21	874.82
4	Net profit for the period after tax (after exceptional and /or extraordinary items)	1,005.81	438.86	1,624.01	583.30
5	Total comprehensive income for the period [Comprising profit for the period (after tax) and other comprehensive income (after tax)]	1,924.42	793.55	1,637.21	1,113.76
6	Equity share capital	1,003.04	1,003.04	1,003.04	1,003.04
7	Other equity				29,241.91
8	Earnings Per Share - Basic (₹) (Not Annualised) - Diluted (₹) (Not Annualised)	1.00 1.00 (Not annualised)	0.44 0.44 (Not annualised)	1.62 1.62 (Not annualised)	0.58 0.58

Notes:

- The above is an extract of the detailed format of the Statement of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Statement of Financial Results of the quarter are available on the websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com and also on the Company's website at www.kokuyocamlin.com. The same can be accessed by scanning QR code provided below.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 08 August 2025. The results have been subjected to a limited review by the Statutory Auditors of the Company who have expressed a modified conclusion thereon.

For Kokuyo Camlin Limited

Dilip Dandekar
Chairman & Non Executive Director

Place : Mumbai
Dated : 8 August 2025

Email address for investors complaints: investorrelations@kokuyocamlin.com

How has ISRO become so successful?
Are there lessons for other technology sectors?

From very humble beginnings to one of the foremost space agencies of the world—how has ISRO reached where it is?

Is ISRO breaking new grounds in space science and technology, or is it indulging only in jugaad and reinventing the wheel?

Challenges ahead: Can ISRO continue scaling new heights by doing more of what it has been doing, or does it need to reinvent itself for greater glory?

Can the success of ISRO be replicated in other technology sectors? What lessons can be learnt from ISRO's journey?

13 AUGUST 2025

06:00 PM

Join us on ZOOM

Dr Mila Mitra
Chief Scientific Officer & Co-Founder, STEM & Space

Amitabh Sinha
Deputy Editor
The Indian Express

Scan to Register

epaper.financialexpress.com

New Delhi

हिसार मेटल इंडस्ट्रीज लिमिटेड

पंजीकृत कार्यालय: नियर इंडस्ट्रियल डेवलपमेंट कॉलोनी, दिल्ली रोड, हिसार-125005 (हरियाणा)
 ईमेल: info@hisarmetal.com; वेबसाइट: www.hisarmetal.com
 फोन: (01662) 220067, 220367, 220738 फैक्स: (01662) 220265 CIN: L74899HR1990PLC030937

30 जून, 2025 को समाप्त तिमाही के लिए अर्न्कक्षित वित्तीय परिणाम

(क. लाखों में निर्विष्ट को छोड़कर)

	विवरण	समाप्त तिमाही 30.06.2025 (अर्न्कक्षित)	समाप्त तिमाही 31.03.2025 (अर्न्कक्षित)	समाप्त तिमाही 30.06.2024 (अर्न्कक्षित)	समाप्त वर्ष 31.03.2025 (अर्न्कक्षित)
1	प्रवालन से कुल आय (अन्य आय सहित)	6233	5981	6355	24556
2	अवधि के लिए शुद्ध लाभ/(हानि) (कर, अपवादात्मक और/व असाधारण मदों से पूर्व)	56	53	115	427
3	कर से पूर्व अवधि के लिए शुद्ध लाभ/(हानि) (अपवादात्मक और/व असाधारण मदों के बाद)	56	53	115	427
4	कर के बाद अवधि के लिए शुद्ध लाभ/(हानि) (अपवादात्मक और/व असाधारण मदों के बाद)	42	38	86	318
5	अवधि के लिए कुल व्यापक आय [अवधि के लिए लाभ/(हानि) (कर के बाद) और अन्य व्यापक आय (कर के बाद) शामिल]	42	38	86	318
6	इक्विटी शेयर पूंजी	540	540	540	540
7	अन्य इक्विटी (पुनर्मुल्यांकन रिजर्व्स को छोड़कर) जैसा कि पिछले वर्ष की अर्न्कक्षित बैलेंस शीट में दिखाया गया है				5741
8	प्रति शेयर आय (क. 10/- प्रत्येक) (ला. और बंद प्रमालनों के लिए)				
9	बैसिक एवं डायल्यूटेड	0.78	0.70	1.59	5.89

नोट:


सेबी (सिस्टमट दायित्व और प्रकटीकरण आवश्यकताओं) नियम, 2015 के नियम 33 के अनुसार, स्टॉक एक्सचेंज के साथ दर्ज की गई कपोलित त्रैमासिक वित्तीय परिणामों का विस्तृत प्रारूप का चंद्रण है। वित्तीय परिणामों का सम्पूर्ण प्रारूप स्टॉक एक्सचेंजों की वेबसाइट (www.bseindia.com व www.nseindia.com) और कंपनी की वेबसाइट (www.hisarmetal.com) पर उपलब्ध है।

कृतो और निदेशक मंडल की ओर से

हस्ता/-
(अधिराम तायल)
 प्रबंध निदेशक
 DIN 00081455

स्थान: हिसार (हरियाणा)
तिथि: अगस्त 09, 2025

THE BUSINESS DAILY FOR DAILY BUSINESS



ARYAMAN

FINANCIAL SERVICES LTD

आर्यमान फाइनेंशियल सर्विसेज लिमिटेड

कॉर्पोरेट पहचान संख्या: L748999DL1994PLC059009

पंजीकृत कार्यालय: 102, गंगा चैबन, 6ए/1, डब्ल्यू.ई.ए., करोल बाग, नई दिल्ली-110005

कॉर्पोरेट कार्यालय: 60, छटाउ बिल्डिंग, ग्राउंड फ्लोर, अलकेश दिनेश मोदी मार्ग,

सामने पी.जे. टॉवर (बीएसई बिल्डिंग), फोर्ट, मुंबई - 400 001

दूरभाष संख्या: 022 - 6216 6999 | फैक्स : 22630434 | ईमेल: www.afsl.co.in |

वेबसाइट: <https://www.afsl.co.in/index.html>

30 जून, 2025 को समाप्त तिमाही के लिए संशोधित

अलेखापरीक्षित वित्तीय परिणाम का सारांश

(लाख रुपये में)

क्र. सं.	विवरण	संशोधित परिणाम			
		समाप्त तिमाही		समाप्त वर्ष	
		30.06.2025 (अलेखापरीक्षित)	31.03.2025 (संशोधित परिणाम)	30.06.2024 (अलेखापरीक्षित)	31.03.2025 (संशोधित परिणाम)
1	कुल आय	3,003.75	4,162.43	1,210.14	11,809.60
2	कर पूर्व अर्पण हेतु निवल लाभ/(हानि) (अपवादित तथा/अथवा असाधारण मदों से पूर्व)	1,563.19	1,218.53	714.12	5,414.78
3	कर पूर्व अर्पण हेतु निवल लाभ/(हानि) (अपवादित तथा/अथवा असाधारण मदों के पश्चात)	1,563.19	1,218.53	714.12	5,414.78
4	कर पश्चात अर्पण हेतु निवल लाभ/(हानि) (अपवादित तथा/अथवा असाधारण मदों के पश्चात)	1,322.43	1,059.20	610.58	4,520.07
5	अर्पण हेतु कुल व्यापक आय [अर्पण हेतु लाभ/हानि (कर पश्चात) तथा अन्य व्यापक आय (कर पश्चात)]	1,599.39	25.60	647.45	5,958.88
6	इक्विटी शेयर पूंजी	1,224.70	1,224.70	1,168.20	1,224.70
7	आधारभूतियाँ (पुनर्मुल्यांकन आधारित को छोड़कर जैसा कि वित्तीय परिणाम में प्रदर्शित है)	11,649.79	6,120.63	6,120.63	6,120.63
8	आय प्रति शेयर (₹. 10/- प्रत्येक के) (सतत तथा असातत परिवर्तनों हेतु) - 1. वार्षिक; 2. डाइव्देंड;	10.80 10.80	9.01 9.01	5.23 5.23	38.64 38.64

स्टैंडअलोन वित्तीय परिणामों के प्रमुख आंकड़े

सेवा (एलओडीआर) के विनियमन 47(1) (बी) के अनुसार, कंपनी को स्टैंडअलोन वित्तीय जानकारी:


परिचालन से कुल आय	274.65	1,212.10	220.09	2,116.24
कर पूर्व निवल लाभ/(हानि)	178.79	485.54	114.22	822.39
कर पश्चात निवल लाभ/(हानि)	133.76	361.17	85.08	611.84

टिप्पणी:

- संगत पिछली अवधि के आंकड़ों को, जहाँ आवश्यक हो, पुनर्समूहित/पुनर्पंजीकृत किया गया है, ताकि उन्हें तुलनीय बनाया जा सके।
- कंपनी का केवल एक ही व्यवसाय अर्थात वित्तीय सेवाएँ और संबंधित गतिविधियाँ हैं, एक खंड जिसमें वह काम करती है।
- इन परिणामों को सांख्यिक लेखा परीक्षकों द्वारा समित समीक्षा को गई है।
- 30 जून, 2025 को समाप्त तिमाही के उपरोक्त परिणामों की समीक्षा 7 अगस्त, 2025 को आयोजित लेखा परीक्षा समिति की बैठक में की गई है और निदेशक मंडल द्वारा 7 अगस्त, 2025 को आयोजित अपनी बैठक में अनुमोदित किया गया है।
- उपरोक्त तिमाही वित्तीय परिणाम कंपनी की वेबसाइट (<http://afsl.co.in/investor-relationship.html>) पर भी अपलोड किए जा रहे हैं।

दिनांक: 07 अगस्त, 2025

स्थान: मुंबई



आर्यमान फाइनेंशियल सर्विसेज लिमिटेड के लिए

हस्ता./-

श्रीपाल शाह

पूর্ণकालिक निदेशक

डीआईएन: 01628855

The image shows the logo of MAX Estates Limited, which consists of a stylized 'M' and 'E' forming a house-like shape, followed by the text 'MAX ESTATES'. To the right of the logo, the company's contact details are listed: CIN: L70200DL2016PLC438718, Corporate Office: Max Towers, L-20, C-001/A/1, Sector-16B, Noida-201301, Uttar Pradesh, India, Registered Office: Max House 1, Dr. Jha Marg, Okhla Phase 3, Opposite Okhla Railway Station, Okhla Industrial Estate, South Delhi, New Delhi, India, 11002, and Website: www.maxestates.in.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS OR INVESTMENT ADVICE. NO OFFER OF SECURITIES, INCLUDING BUT NOT LIMITED TO, AN EQUITY OFFERING, PRIVATE PLACEMENT, FOLLOW-ON PUBLIC OFFERING, DEBT OFFERING, PIPE, RIGHTS ISSUE, WARRANT OFFERING, CONVERTIBLE BOND OFFERING, OR ANY OTHER FORM OF SECM OFFERING, WILL BE MADE BY THE COMPANY WITHOUT THE ISSUANCE OF A SEPARATE PROSPECTUS DOCUMENT.

BIO MEDICA LABORATORIES LIMITED

(Formerly Known as Bio Medica Laboratories Private Limited)

CIN: U24230MP2015PLC034576

Our Company was originally incorporated as a private limited company with the name of “Bio Medica Laboratories Private Limited” under the Companies Act, 1932 vide certificate of incorporation dated August 14, 2015, issued by Registrar of Companies, Gwalior, bearing CIN U24230MP2015PTCO34576. Further, our Company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of our Company at the Extra-Ordinary General Meeting held on September 09, 2024 & name of our Company changed from “Bio Medica Laboratories Private Limited” to “Bio Medica Laboratories Limited” & Registrar of Companies, CPC has issued a new certificate of incorporation consequent upon conversion dated October 24, 2024, bearing CIN: U24230MP2015PLC034576. For further details of incorporation please refer to section titled “Our History and Certain Other Corporate Matters” beginning on page no. 204 of this Draft Red Herring Prospectus.

Registered Office: Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Indore Estate (Indore), Indore, Madhya Pradesh – 452015, India
Phone No.: +91- 7314102751; **Fax:** N.A.; **Website:** www.biomedica.co.in; **E-mail:** companysecretary@biomedica.co.in
Company Secretary and Compliance Officer: Mr. Rahul Kumar

OUR PROMOTERS: MR. MUKESH MEHTA AND MR. PRADEEP MEHTA

THE ISSUE

INITIAL PUBLIC OFFERING OF UP TO 37,71,600 EQUITY SHARES OF RS. 10/- EACH (“EQUITY SHARES”) OF BIO MEDICA LABORATORIES LIMITED (“BIO MEDICA” OR “BML” OR THE “COMPANY” OR THE “ISSUER”) FOR CASH AT A PRICE OF RS. [•] /- PER EQUITY SHARE (THE “ISSUE PRICE”), AGGREGATING TO RS. [•] LAKHS (“THE ISSUE”) COMPRISING A FRESH ISSUE OF UP TO 33,94,800 EQUITY SHARES AGGREGATING TO RS. [•] LAKHS BY OUR COMPANY (“FRESH ISSUE”) AND AN OFFER FOR SALE OF UP TO 1,88,400 EQUITY SHARES BY MUKESH MEHTA AND UP TO 1,88,400 EQUITY SHARES BY PRADEEP MEHTA (“THE PROMOTER” OR “THE SELLING SHAREHOLDER”) AGGREGATING TO RS. [•] LAKHS (“OFFER FOR SALE”). OUT OF THE ISSUE, 1,89,600 EQUITY SHARES AGGREGATING TO RS. [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER (“MARKET MAKER RESERVATION PORTION”), THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 35,82,000 EQUITY SHARES OF FACE VALUE OF RS. 10/- EACH AT AN ISSUE PRICE OF RS. [•] /- PER EQUITY SHARE AGGREGATING TO RS. [•] LAKHS IS HEREINAFTER REFERRED TO AS THE “NET ISSUE”. THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 29.99% AND 28.49%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF [•] (WHICH ARE WIDELY CIRCULATED ENGLISH DAILY NEWSPAPER) AND ALL EDITIONS OF [•] (WHICH ARE WIDELY HINDI DAILY NEWSPAPER) AND ALL EDITIONS OF [•] THE REGIONAL LANGUAGE OF MADHYA PRADESH, WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE”, “STOCK EXCHANGE”) FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten working days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing, extends the Bid/Issue Period for a minimum of one working day, subject to the Bid/Issue Period not exceeding ten working days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs” (the “QIB Portion”), provided that our Company in consultation with the BRLM may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (“Net QIB Portion”). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Individual Investors who applies for minimum application size, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see “Issue Procedure” on page 305 of this Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulation 247 of SEBI (ICDR) Regulations, 2018 and SEBI (ICDR) (Amendment) Regulations, 2025 vide notification dated March 03rd, 2025, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015, to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on August 08, 2025. Pursuant to Regulation 247 of the SEBI ICDR Regulations, the Draft Red Herring Prospectus filed with NSE Emerge shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents# sme_offer, on the website of the BRLM at www.narnolia.com and also on the website of the Company at www.biomedica.co.in. Our Company invites the public to give comments on the Draft Red Herring Prospectus filed with NSE Emerge with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or the Company Secretary & Compliance Officer of our Company, and/or to the BRLM in relation to the offer on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with NSE Emerge.

Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section “Risk Factors” beginning on page 28 of this Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on EmERGE Platform of NSE (“NSE EmERGE”).

For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see “Capital Structure” beginning on page 69 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see “Our History and Certain Other Corporate Matters” beginning on page 204 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 NARNOLIA FINANCIAL SERVICES LIMITED SEBI Registration No.: INM000010791 Address: 201, 2nd Floor, Marble Arch, 236 B A J C, Bose Road, Kolkata, West Bengal- 700020, India. Telephone No: 033- 40501500 Website: www.narnolia.com Email ID: ipo@narnolia.com Contact Person: Mr. Rajveer Singh	 SKYLINE FINANCIAL SERVICES PRIVATE LIMITED SEBI Registration No.: INR0000003241 Address: D-153 A, 1st Floor, Okhla Industrial Area, Phase -I, New Delhi-110020 Telephone No.: +91-11-40450193-97 Email: ipo@skylinertn.com Website: www.skylinertn.com Contact Person: Mr. Anuj Rama	Mr. Rahul Kumar Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh-452015, India Tel: +91-7314102751 Email: companysecretary@biomedica.co.in Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.
All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.		
<p style="text-align: right;">For BIO MEDICA LABORATORIES LIMITED On Behalf of the Board of Directors Sd/- Mr. Rahul Kumar Company Secretary and Compliance Officer</p>		
Place: Indore Date: August 09, 2025		
<p>Disclaimer: BIO MEDICA LABORATORIES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on August 08, 2025. The Draft Red Herring Prospectus is available on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents-smf and is available on the websites of the BRLM at www.narnolia.com and also on the website of the Company at www.biomedica.co.in. Any potential investors should note that Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 28 of this Draft Red Herring Prospectus.</p> <p>The Equity Shares have not been and will not be registered under the U.S Securities Act of 1933, as amended (U.S. Securities Act) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S Persons (as defined in Regulation), except pursuant to exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transaction in reliance on Regulation S under the U.S Securities Act and the applicable laws of the jurisdiction where those offers and sale occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.</p>		